179 related articles for article (PubMed ID: 24043462)
1. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function.
Lee JJ; Jeong HJ; Kim MK; Wee WR; Lee WW; Kim SU; Sung C; Yang YH
Purinergic Signal; 2014; 10(2):357-65. PubMed ID: 24043462
[TBL] [Abstract][Full Text] [Related]
2. CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.
Wang LL; Tang HP; Shi GC; Wan HY; Tang W; Hou XX; Pan LN; Shi BY; Tao LQ
Mol Med Rep; 2013 Nov; 8(5):1432-8. PubMed ID: 24065069
[TBL] [Abstract][Full Text] [Related]
3. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation.
Chen M; Su W; Lin X; Guo Z; Wang J; Zhang Q; Brand D; Ryffel B; Huang J; Liu Z; He X; Le AD; Zheng SG
Arthritis Rheum; 2013 May; 65(5):1181-93. PubMed ID: 23400582
[TBL] [Abstract][Full Text] [Related]
5. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
[No Abstract] [Full Text] [Related]
6. CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease.
Liberal R; Grant CR; Ma Y; Csizmadia E; Jiang ZG; Heneghan MA; Yee EU; Mieli-Vergani G; Vergani D; Robson SC; Longhi MS
J Autoimmun; 2016 Aug; 72():102-12. PubMed ID: 27210814
[TBL] [Abstract][Full Text] [Related]
7. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
Allard B; Longhi MS; Robson SC; Stagg J
Immunol Rev; 2017 Mar; 276(1):121-144. PubMed ID: 28258700
[TBL] [Abstract][Full Text] [Related]
8. Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors.
Chatterjee S; Thyagarajan K; Kesarwani P; Song JH; Soloshchenko M; Fu J; Bailey SR; Vasu C; Kraft AS; Paulos CM; Yu XZ; Mehrotra S
Cancer Res; 2014 Nov; 74(21):6048-59. PubMed ID: 25205101
[TBL] [Abstract][Full Text] [Related]
9. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.
Sauer AV; Brigida I; Carriglio N; Hernandez RJ; Scaramuzza S; Clavenna D; Sanvito F; Poliani PL; Gagliani N; Carlucci F; Tabucchi A; Roncarolo MG; Traggiai E; Villa A; Aiuti A
Blood; 2012 Feb; 119(6):1428-39. PubMed ID: 22184407
[TBL] [Abstract][Full Text] [Related]
10. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
Baghbani E; Noorolyai S; Shanehbandi D; Mokhtarzadeh A; Aghebati-Maleki L; Shahgoli VK; Brunetti O; Rahmani S; Shadbad MA; Baghbanzadeh A; Silvestris N; Baradaran B
Life Sci; 2021 Oct; 282():119826. PubMed ID: 34265363
[TBL] [Abstract][Full Text] [Related]
11. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4
Han L; Sugiyama H; Zhang Q; Yan K; Fang X; McCormick TS; Cooper KD; Huang Q
Australas J Dermatol; 2018 Feb; 59(1):e31-e38. PubMed ID: 28295154
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of aging mice to listeriosis: Role of anti-inflammatory responses with enhanced Treg-cell expression of CD39/CD73 and Th-17 cells.
Alam MS; Cavanaugh C; Pereira M; Babu U; Williams K
Int J Med Microbiol; 2020 Feb; 310(2):151397. PubMed ID: 31974050
[TBL] [Abstract][Full Text] [Related]
13. Activin-A limits Th17 pathogenicity and autoimmune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-α-dependent pathways.
Morianos I; Trochoutsou AI; Papadopoulou G; Semitekolou M; Banos A; Konstantopoulos D; Manousopoulou A; Kapasa M; Wei P; Lomenick B; Belaidi E; Kalamatas T; Karageorgiou K; Doskas T; Sallusto F; Pan F; Garbis SD; Quintana FJ; Xanthou G
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12269-12280. PubMed ID: 32409602
[TBL] [Abstract][Full Text] [Related]
14. CD73 and adenosine generation in the creation of regulatory microenvironments.
Regateiro FS; Cobbold SP; Waldmann H
Clin Exp Immunol; 2013 Jan; 171(1):1-7. PubMed ID: 23199317
[TBL] [Abstract][Full Text] [Related]
15. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
16. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
17. Purinergic Signaling as a Regulator of Th17 Cell Plasticity.
Fernández D; Flores-Santibáñez F; Neira J; Osorio-Barrios F; Tejón G; Nuñez S; Hidalgo Y; Fuenzalida MJ; Meza D; Ureta G; Lladser A; Pacheco R; Acuña-Castillo C; Guixé V; Quintana FJ; Bono MR; Rosemblatt M; Sauma D
PLoS One; 2016; 11(6):e0157889. PubMed ID: 27322617
[TBL] [Abstract][Full Text] [Related]
18. Human gingiva-derived mesenchymal stem cells are therapeutic in lupus nephritis through targeting of CD39
Dang J; Xu Z; Xu A; Liu Y; Fu Q; Wang J; Huang F; Zheng Y; Qi G; Sun B; Bellanti JA; Kandalam U; Emam HA; Jarjour W; Zheng SG
J Autoimmun; 2020 Sep; 113():102491. PubMed ID: 32565049
[TBL] [Abstract][Full Text] [Related]
19. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
Fletcher JM; Lonergan R; Costelloe L; Kinsella K; Moran B; O'Farrelly C; Tubridy N; Mills KH
J Immunol; 2009 Dec; 183(11):7602-10. PubMed ID: 19917691
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
